Anthelio Healthcare Solutions

antheliohealth.com

Anthelio is now Atos. Anthelio is the largest independent provider of healthcare technology solutions in the market. We offer solutions across the spectrum of care, providing customers the ability to solve their critical technology needs from a single source while delivering cost savings and efficiencies. Our end-to-end solutions include IT infrastructure services, IT applications management, EHR optimization, Patient Engagement, Analytics, and Revenue Cycle Management (RCM) including HIM Services, Patient Financial Services and Cancer Registry Services. Anthelio drives sustainable value to over 63,000 physicians and nurses in hundreds of healthcare organizations supporting their annual revenue of over $67 billion and impacting quality care to over 60 million patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

NEUROBO PHARMACEUTICALS, INC. AND DONG-A ST CO. LTD. ANNOUNCE STRATEGIC COLLABORATION

NeuroBo Pharmaceuticals, Inc. | September 16, 2022

news image

NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co., Ltd. announced that they have entered into a conditional exclusive license agreement for NeuroBo to develop and commercialize DA-1241 and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis obesity and type 2 diabetes. DA-1241 is a novel G-Protein-Coupled Receptor 119 agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucos...

Read More

J&J LAUNCHES ‘MULTI-PRONGED’ CORONAVIRUS RESPONSE

PharmaTimes | January 30, 2020

news image

The company has initiated efforts to broadly collaborate with others in order to screen a library of antiviral therapies, hoping to identify compounds with antiviral activity against the virus – which is also known as 2019-nCoV or Wuhan coronavirus. Using its AdVac and PER.C6 technologies - the same technologies that were used in the development and manufacturing of Janssen's investigational Ebola vaccine - J&J has revealed plans to try and rapidly upscale production of the optimal...

Read More

ALLIED EXPANDS PHARMACEUTICAL PIPELINE BY FILING US PROVISIONAL PATENT FOR PSILOCYBIN BASED THERAPEUTICS

Allied Corp | October 21, 2020

news image

Allied Corp, an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce the filing of a new United States provisional patent application entitled “PSILOCYBIN COMPOSITIONS AND FORMULATIONS AND THEIR USE IN TREATING MENTAL HEALTH DISORDERS AND IMPROVING MENTAL HEALTH”. The provisional patent application covers a novel combination of psilocybin and proprietary mushroom f...

Read More

Pharmacy Market

IONIS ENTERS COLLABORATION TO ADVANCE NEXT GENERATION PROGRAM TARGETING LP(A) FOR CARDIOVASCULAR DISEASE

PRNewswire | August 04, 2023

news image

Ionis Pharmaceuticals, Inc. announced that it has entered a collaboration and license agreement with Novartis for the discovery, development and commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven cardiovascular disease (CVD). This builds on the companies' existing collaboration focused on the development and commercialization of pelacarsen, which Novartis is currently evaluating in a Phase 3 cardiovascular outcome study. The next generation compound...

Read More
news image

Business Insights

NEUROBO PHARMACEUTICALS, INC. AND DONG-A ST CO. LTD. ANNOUNCE STRATEGIC COLLABORATION

NeuroBo Pharmaceuticals, Inc. | September 16, 2022

NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co., Ltd. announced that they have entered into a conditional exclusive license agreement for NeuroBo to develop and commercialize DA-1241 and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis obesity and type 2 diabetes. DA-1241 is a novel G-Protein-Coupled Receptor 119 agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucos...

Read More
news image

J&J LAUNCHES ‘MULTI-PRONGED’ CORONAVIRUS RESPONSE

PharmaTimes | January 30, 2020

The company has initiated efforts to broadly collaborate with others in order to screen a library of antiviral therapies, hoping to identify compounds with antiviral activity against the virus – which is also known as 2019-nCoV or Wuhan coronavirus. Using its AdVac and PER.C6 technologies - the same technologies that were used in the development and manufacturing of Janssen's investigational Ebola vaccine - J&J has revealed plans to try and rapidly upscale production of the optimal...

Read More
news image

ALLIED EXPANDS PHARMACEUTICAL PIPELINE BY FILING US PROVISIONAL PATENT FOR PSILOCYBIN BASED THERAPEUTICS

Allied Corp | October 21, 2020

Allied Corp, an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce the filing of a new United States provisional patent application entitled “PSILOCYBIN COMPOSITIONS AND FORMULATIONS AND THEIR USE IN TREATING MENTAL HEALTH DISORDERS AND IMPROVING MENTAL HEALTH”. The provisional patent application covers a novel combination of psilocybin and proprietary mushroom f...

Read More
news image

Pharmacy Market

IONIS ENTERS COLLABORATION TO ADVANCE NEXT GENERATION PROGRAM TARGETING LP(A) FOR CARDIOVASCULAR DISEASE

PRNewswire | August 04, 2023

Ionis Pharmaceuticals, Inc. announced that it has entered a collaboration and license agreement with Novartis for the discovery, development and commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven cardiovascular disease (CVD). This builds on the companies' existing collaboration focused on the development and commercialization of pelacarsen, which Novartis is currently evaluating in a Phase 3 cardiovascular outcome study. The next generation compound...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us